Svb Leerink reiterated their market perform rating on shares of Synthorx (NASDAQ:THOR) in a research note published on Wednesday morning, BenzingaRatingsTable reports. Svb Leerink currently has a $68.00 price objective on the medical instruments supplier’s stock.
Several other equities analysts have also recently weighed in on THOR. Zacks Investment Research upgraded Synthorx from a hold rating to a buy rating and set a $22.00 price objective on the stock in a research note on Saturday, November 9th. Leerink Swann lowered Synthorx from an outperform rating to a market perform rating and set a $68.00 target price for the company. in a research report on Wednesday. HC Wainwright lowered Synthorx from a buy rating to a neutral rating in a research report on Tuesday. Evercore ISI reaffirmed a buy rating and set a $35.00 target price on shares of Synthorx in a research report on Sunday, November 24th. Finally, ValuEngine raised Synthorx from a hold rating to a buy rating in a research report on Thursday, December 5th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Synthorx presently has an average rating of Buy and an average price target of $40.67.
NASDAQ:THOR traded up $0.18 during trading hours on Wednesday, hitting $68.03. 654,775 shares of the company traded hands, compared to its average volume of 495,711. The firm’s 50-day simple moving average is $21.66 and its 200-day simple moving average is $16.96. Synthorx has a one year low of $11.00 and a one year high of $68.05.
Synthorx (NASDAQ:THOR) last issued its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.12. On average, sell-side analysts forecast that Synthorx will post -1.54 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Rhumbline Advisers purchased a new stake in shares of Synthorx during the 3rd quarter valued at $174,000. Wells Fargo & Company MN increased its position in shares of Synthorx by 156.5% during the 2nd quarter. Wells Fargo & Company MN now owns 12,056 shares of the medical instruments supplier’s stock valued at $162,000 after purchasing an additional 7,356 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Synthorx by 31.6% during the 3rd quarter. California State Teachers Retirement System now owns 14,909 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 3,580 shares during the last quarter. First Trust Advisors LP purchased a new stake in shares of Synthorx during the 3rd quarter valued at $310,000. Finally, Virtus ETF Advisers LLC purchased a new stake in Synthorx in the 2nd quarter worth about $282,000. 66.11% of the stock is owned by hedge funds and other institutional investors.
Synthorx Company Profile
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Recommended Story: Intrinsic Value and Stock Selection
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.